Proton pump inhibitors increase the risk of bone fracture in patients with comorbidities: a review
DOI:
https://doi.org/10.33448/rsd-v11i15.29302Keywords:
Proton Pump Inhibitor; Bone Fracture; Drug adverse reactions; Health; Teaching.Abstract
The present study aimed to know the scientific evidence on the relationship of increased risk of bone fracture with the use of proton pump inhibitors (IBP's) in patients with pre-existing comorbidities. A literature review of scientific articles published on the PubMed platform was carried out, including all original articles in the last five years, according to the pre-established inclusion criteria. It was observed that the risk of bone fracture is associated with the time of use of IBPs in patients with different age groups, with or without comorbidities, among which we can mention osteoporosis and diabetes as the most prevalent. It was also evidenced that patients on hemodialysis or those with liver cirrhosis are at increased risk for bone fractures. Continuing, it was possible to verify that the use of these drugs in gastroesophageal reflux disease in pregnant women does not affect the fetal bones to a clinically significant extent. The results of this review allow us to suggest that caution should be exercised in prescribing this class of drug, in addition to monitoring this adverse event regarding its use depending on the target population, and caution should be exercised in prescribing the dose and duration of treatment. Therefore, attention is drawn to the appearance of fractures, especially in view of how this impairs the quality of life of patients who need to undergo anti-ulcer therapy for a long time.
References
Castellana, C., Pecere, S., Furnari, M., Telese, A., Matteo, M. V., Haidry, R., & Eusebi, L. H. (2021). Side effects of long-term use of proton pump inhibitors: practical considerations. Polish archives of internal medicine-polskie archiwum medycyny wewnetrznej, 131(6), 541-549.
Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017). ACG clinical guideline: treatment of Helicobacter pylori infection. Official journal of the American College of Gastroenterology| ACG, 112(2), 212-239.
Chou, Y. S., Jiang, H. J., Chen, C. H., Ho, P. S., & Lee, T. C. (2020). Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes. Scientific reports, 10(1), 1-8.
Durrani, S., & Rothenberg, M. (2017). Recent advances in eosinophilic esophagitis. F1000Research, 6.
Fattahi, M. R., Niknam, R., Shams, M., Anushiravani, A., Taghavi, S. A., Omrani, G. R., & Mahmoudi, L. (2019). The association between prolonged proton pump inhibitors use and bone mineral density. Risk management and healthcare policy, 12, 349.
Fusaro, M., D'Arrigo, G., Pitino, A., Iervasi, G., Tentori, F., Robinson, B., ... & Tripepi, G. (2019). Increased risk of bone fractures in hemodialysis patients treated with proton pump inhibitors in real world: results from the Dialysis outcomes and practice patterns study (DOPPS). Journal of Bone and Mineral Research, 34(12), 2238-2245.
Kendler, D. L., Marin, F., Geusens, P., López-Romero, P., Lespessailles, E., Body, J. J., & Minisola, S. (2020). Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Bone, 130, 115113.
Kim, J. J., Jang, E. J., Park, J., & Sohn, H. S. (2020). Association between proton pump inhibitor use and risk of fracture: A population-based case-control study. PloS one, 15(7), e0235163.
Labenz, C., Wörns, M. A., Adarkwah, C. C., Galle, P. R., Schattenberg, J. M., & Kostev, K. (2020). Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population‐based study. Alimentary Pharmacology & Therapeutics, 52(6), 1042-1050.
Lenihan, C. R., Nair, S. S., Vangala, C., Ramanathan, V., Montez-Rath, M. E., & Winkelmayer, W. C. (2017). Proton pump inhibitor use and risk of hip fracture in kidney transplant recipients. American Journal of Kidney Diseases, 69(5), 595-601.
Min, Y. W., Lee, Y. C., Kim, K., Ryu, S., Hong, K. S., Jeon, H. H., ... & Rhee, P. L. (2020). Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study. The Korean journal of internal medicine, 35(5), 1084.
Miyano, S., Michihata, N., Sada, K.-E., Uda, K., Matsui, H., Fushimi, K., . . . Yasunaga, H. J. R. (2021). Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case–control study. 60(4), 1717-1723.
Ock, M., Lee, S., & Kim, H. (2022). Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co‐administration in patients with type 2 diabetes mellitus. Journal of Clinical Pharmacy and Therapeutics.
Park, J.-H., Song, Y.-M., Jung, J.-H., & Han, K. J. B. (2020). Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study. 135, 115306.
Sampaio, L. G., Marques, J., Petterle, R. R., Moreira, C. A., & Borba, V. Z. C. (2021). Association between fractures and traditional risk factors for osteoporosis and low bone mineral density in patients with obesity. Archives of Endocrinology and Metabolism, 65, 152-163.
Strand, D. S., Kim, D., Peura, D. A. J. G., & liver. (2017). 25 years of proton pump inhibitors: a comprehensive review. 11(1), 27.
Vicentini, M., Mancuso, P., Giorgi Rossi, P., Di Pede, S., Pellati, M., Gandolfi, A., ... & Ferretti, A. (2019). A cluster randomized trial to measure the impact on nonsteroidal anti-inflammatory drug and proton pump inhibitor prescribing in Italy of distributing cost-free paracetamol to osteoarthritic patients. BMC family practice, 20(1), 1-9.
Wang, Y. H., Wintzell, V., Ludvigsson, J. F., Svanström, H., & Pasternak, B. (2020). Association between proton pump inhibitor use and risk of fracture in children. JAMA pediatrics, 174(6), 543-551.
Wei, J., Chan, A. T., Zeng, C., Bai, X., Lu, N., Lei, G., & Zhang, Y. J. B. (2020). Association between proton pump inhibitors use and risk of hip fracture: a general population-based cohort study. 139, 115502.
Li, J., Xie, X., Liu, W., Gu, F., Zhang, K., Su, Z., ... & Yu, T. (2021). Acid-Suppressive Drugs and Risk of Fracture in Children and Young Adults: A Meta-Analysis of Observational Studies. Frontiers in Pharmacology, 1804.
Yang, X., Li, Y., Sun, Y., Zhang, M., Guo, C., Mirza, I. A., & Li, Y. Q. (2018). Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Digestive Diseases and Sciences, 63(2), 302-311.
Yu, L., Luo, L., Long, X., Liang, X., Ji, Y., Graham, D. Y., & Lu, H. (2019). High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line Helicobacter pylori therapy: a randomized trial. Helicobacter, 24(4), e12596.
Zanaty, M. I., Abdel-Moneim, A., Kitani, Y., Sekiguchi, T., & Suzuki, N. (2021). Effect of Omeprazole on Osteoblasts and Osteoclasts in vivo and in the in vitro Model Using Fish Scales. Biochemistry (Moscow), 86(10), 1192-1200.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Rachel Melo Ribeiro; Natália Silva de Carvalho; Jhônata Costa Moura; Natália Carvalho Fonsêca; Karen Marayanne Torres Cavalcante Barros; Vanessa Almeida Silva; Moisés Lucas Braz; Beatriz da Silva Ferreira de Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
